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1. Introduction
Ovarian cancer is the fifth leading cause of cancer death in the United States, and contrib‐
utes significantly to the worldwide cancer burden [1]. The lack of gynecologic-specific
symptoms and effective early detection methods for ovarian cancer leads to a preponder‐
ance of late-stage diagnoses. Ovarian cancer is a surgically-staged and treated disease, and
the application of appropriate, guidelines-based treatment is currently the only option to re‐
duce ovarian cancer mortality [2].
The National Comprehensive Cancer Network (NCCN) [3] and the National Institutes of
Health (NIH) [4] publish widely used treatment guidelines for ovarian cancer cases in the
United States. Both NCCN and NIH’s Physician Data Query (PDQ) incorporate tumor his‐
tology into treatment guidelines. While the NCCN publishes guidelines for the three main
types of ovarian cancer, epithelial, sex cord-stromal, and germ cell tumors [5]; the PDQ of‐
fers guidelines only for the most common epithelial tumors. While epithelial tumors account
for about 90% of all ovarian neoplasms, they are not a homogenous group [5]. The four main
epithelial subtypes (serous, mucinous, clear cell, and endometrioid) can have very different
clinical and pathologic patterns.
Among  epithelial  ovarian  cancer  subtypes  is  mucinous  epithelial  ovarian  cancer
(mEOC), a relatively rare subtype accounting for approximately 14% of invasive ovarian
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cancer  cases  [6].  mEOC has  a  distinct  natural  history compared to  other  epithelial  sub‐
types, especially the most common serous subtype. mEOCs are more often diagnosed in
younger women [6] than other epithelial tumors, and epidemiologic studies have shown
a lack of protective effect from parity and oral contraceptive use [7-11]. Pathologic stud‐
ies  have determined that  mutations in the K-ras  oncogene are  more common in mEOC
compared to other subtypes [12],  while mutations in the BRCA1 tumor suppressor gene
are  less  common  [13].  Despite  their  distinctive  nature,  mEOCs  are  included  in  overall
epithelial  ovarian  cancer  treatment  guidelines,  as  standard  care  for  all  epithelial  sub‐
types is defined in the same manner [3,4].
Because of the differences in risk factors and presentation, a few studies have examined dif‐
ferences in outcomes of mEOC compared to other epithelial subtypes. Many have found
lower response rates to chemotherapy and inferior outcomes compared to other subtypes
[14-16]. Based on these results, it has been suggested that mEOC be treated as a different en‐
tity and not grouped along with epithelial tumors in standard treatment and also in clinical
trials for epithelial ovarian cancer [17]; however, these suggestions have yet to be widely
adopted or implemented. While the existing evidence seems consistent, studies producing
this evidence have contained small numbers and generally represent the experience of indi‐
vidual institutions.
1.1. Objectives
The objective of this chapter is to fully characterize mEOC using a population-based ap‐
proach. We add to the paucity of existing literature on mEOC with an analysis that utilizes
ovarian cancer medical record data from two large populations in the United States, New
York and Northern California. We comprehensively examine demographics, pathologic
characteristics, and the outcomes of treatment for mEOC. We compare these characteristics
to other epithelial subtypes in order to determine whether clinical presentation or outcomes
differ among epithelial subtypes. Finally, we discuss the results of this research in the con‐
text of published studies on mEOC.
2. Study design
2.1. Setting and population
The data presented and analyzed here are from the Ovarian Cancer Treatment Patterns and
Outcomes (OCTPO) study, funded by the Centers for Disease Control and Prevention
(CDC), and conducted by the New York State and the California Cancer Registries [18-20].
The New York State Cancer Registry (NYSCR) conducts surveillance on all 19 million New
York state residents, and the two components of the California Cancer Registry (CCR) that
were funded for this study serve the contiguous geographical area of Greater San Francisco-
San Jose and Sacramento regions, providing surveillance for a population of 9 million resi‐
dents in California. Both the NYSCR and the CCR conduct high quality, population-based
cancer surveillance, and routinely review medical records to abstract demographics, tumor
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characteristics and treatment data as part of state-mandated cancer surveillance. For this ret‐
rospective study, additional detailed patient, tumor, and treatment data were collected by
these registries from multiple sources including hospital, outpatient facility and physician
records. Vital status was determined by linkage with the National Death Index http://
www.cdc.gov/nchs/ndi.htm. The study population included patients with invasive epithe‐
lial ovarian cancer diagnosed between 1998 and 2000. Only invasive cases of epithelial ovari‐
an cancer were included; benign and low malignant potential tumors were excluded.
Primary peritoneal cancers and fallopian tube cancers were also excluded. Subjects diag‐
nosed at autopsy or by death certificate were ineligible. All cases included were histological‐
ly confirmed. Cases were followed up for six years for vital status information.
2.2. Data classification
Histology was collected according to World Health Organization International Classification
of Diseases for Oncology, third edition (ICD-O-3) morphology codes [21]. All epithelial his‐
tologies collected were collapsed into categories for analysis according to Table 1.
Epithelial Ovarian Cancer (EOC) Subtype ICD-O-3 Codes
Mucinous (mEOC) 8470, 8471, 8480, 8481
Serous 8441,8442,8460,8461,8462
Other
(includes endometrioid, clear cell, Brenner, mixed,




Table 1. Histologic definitions by epithelial ovarian cancer subtype
Race and ethnicity was categorized as white non-Hispanic, black non-Hispanic, Asian non-
Hispanic, and Hispanic. A total of 34 cases were excluded from the analysis on the basis of
race or ethnicity data. Three of the 34 cases were classified as American Indian/Alaska Na‐
tive race; these were excluded because of the inability to draw any conclusions from this
race because of the very small number. The remaining 31 cases were excluded because race
or ethnicity information was unspecified or missing. Stage was defined using the Interna‐
tional Federation of Gynecology and Obstetrics (FIGO) system, with categories I, II, III IV, or
unknown. Grade was collapsed into four categories defined as Grade I (well differentiated
tumors), Grade II (moderately differentiated tumors), Grade III/IV (poorly differentiated
and undifferentiated tumors) and unknown grade. Laterality was collapsed into unilateral
(single ovary involved at diagnosis: right, left, or unspecified), or bilateral (both ovaries in‐
volved at diagnosis) categories. Comorbidity was defined using the Deyo-Charlson Comor‐
bidity Index [22, 23], a commonly used measure of disease burden. Comorbidity
information was collected via linkage with state hospital discharge data. Any comorbidity
present in the 12 months prior to or 4 months following an ovarian cancer diagnosis was
included. Type of treatment was defined to distinguish patients who received various com‐
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binations of surgery and chemotherapy. In descriptive analyses, chemotherapy was further
categorized by receipt of specific agents. These categories consisted of surgery and platinum
agent (cisplatin or carboplatin) receipt, surgery and platinum agent and paclitaxel receipt
(standard treatment for EOC) [24], and surgery and any chemotherapy agent or combination
of agents other than cisplatin, carboplatin, or paclitaxel.
2.3. Analyses
Statistical testing was performed using the likelihood ratio chi-square test for discrete varia‐
bles. The Kruskal-Wallis test was used to test for differences among continuous variables. A
generalized logits model was fit to determine the characteristics associated with epithelial
subtype. Variables included in the model were age, race/ethnicity, stage, grade, and laterali‐
ty. Age was transformed in all models using restricted cubic spline functions to allow for
nonlinearity [25]. Due to the lack of availability of grade and stage information for some cas‐
es (31% for grade; 15% for stage), missing indicator variables were included for each varia‐
ble in all models. Because of potential issues with using missing indicator variables, separate
models that imputed missing data were fit (data not shown) [26,27]. These models yielded
consistent results with the un-imputed models. Six-year survival curves are presented as
Kaplan-Meier estimates. Statistical testing for differences in unadjusted survival rates across
epithelial subtypes was performed using the log-rank test. For adjusted survival, a time-de‐
pendent Cox model was used to determine the predictors of six-year survival. Age, race/
ethnicity, stage, grade, epithelial subtype, comorbidity, laterality, surgery, and chemothera‐
py were included as covariates in the survival model. Time-dependent covariates for sur‐
gery and chemotherapy were used to prevent an artificial inflation of the association
between treatment and survival. Cases were considered as not receiving treatment until the
date of the procedure; they were considered as having received treatment after the date of
the procedure. Interactions between epithelial subtype and treatment were included to de‐
termine if the effects of surgery and chemotherapy varied across subtypes. The proportional
hazards assumption was assessed using time-dependent covariates and the Schoenfeld re‐
sidual correlation test. Laterality was found to violate the proportional hazards (PH) as‐
sumption. Stratified log[-log S(t)] plots were used to help determine time intervals within
which the PH assumption held. An interaction between laterality and time was included in
the final model to satisfy the PH assumption.
3. Results
3.1. Demographic and clinical characteristics of mucinous epithelial ovarian cancer
The characteristics of ovarian cancer cases in New York and Northern California are pre‐
sented by epithelial subtype in Table 2. Overall, 230 (8.7%) tumors were mEOC, 1195 (45.3%)
tumors were serous EOC, and 1211 (45.9%) were other EOC. mEOCs were diagnosed at
younger ages (57 years) compared to other subtypes (62 years for serous, 63 years for other
EOCs). Relatively higher percentages of mEOCs were found among black non-Hispanic
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(8.0% vs. 5.9 and 6.7%) and Asian non-Hispanic (14.2% vs. 5.4 and 9.8%) populations com‐
pared to serous and other EOCs. Lower percentages of mEOCs (5.8%) were found among
Hispanics compared to serous and mEOCs (7.5 and 7.7%). mEOCS were more likely to be
diagnosed at FIGO stage I (45.2%) compared to serous (10.0%) and other mEOCs (24.9%).
Higher percentages of low grade tumors and unilateral ovarian involvement at diagnosis
were also present with mEOCs compared to other EOC types. A little under half of mEOC
patients (46.3%) were treated with surgery only and 39.0% were treated with surgery plus a






Age at diagnosis* 57 (45, 72) 62 (52, 72) 63 (51, 75) <0.001
Race/Ethnicity <0.001
White Non-Hispanic 162 (72.0%) 956 (81.3%) 910 (75.8%)
Black Non-Hispanic 18 (8.0%) 69 (5.9%) 80 (6.7%)
Asian Non-Hispanic 32 (14.2%) 63 (5.4%) 118 (9.8%)
Hispanic 13 (5.8%) 88 (7.5%) 93 (7.7%)
FIGO Stage <0.001
I 104 (45.2%) 119 (10.0%) 302 (24.9%)
II 26 (11.3%) 66 (5.5%) 125 (10.3%)
III 62 (27.0%) 747 (62.5%) 380 (31.4%)
IV 19 (8.3%) 153 (12.8%) 225 (18.6%)
Unknown 19 (8.3%) 110 (9.2%) 179 (14.8%)
Grade <0.001
I 73 (31.7%) 80 (6.7%) 92 (7.6%)
II 69 (30.0%) 223 (18.7%) 193 (15.9%)
III/IV 30 (13.0%) 730 (61.1%) 493 (40.7%)
Unknown 58 (25.2%) 162 (13.6%) 433 (35.8%)
Laterality <0.001
Unilateral 167 (77.7%) 410 (36.7%) 634 (67.7%)
Bilateral 48 (22.3%) 707 (63.3%) 302 (32.3%)
Comorbidity 0.0257
None 161 (74.5%) 847 (77.6%) 814 (74.9%)
1 38 (17.6%) 181 (16.6%) 170 (15.6%)
2 or more 17 (7.9%) 63 (5.8%) 103 (9.5%)









Surgery only 95 (46.3%) 132 (12.2%) 196 (17.9%)
Surgery+Platinum 7 (3.4%) 46 (4.3%) 28 (2.6%)
Surgery+Platinum+ Paclitaxel 80 (39.0%) 826 (76.5%) 565 (51.6%)
Surgery+other chemotherapy 2 (1.0%) 21 (1.9%) 12 (1.1%)
Chemotherapy only 12 (5.9%) 32 (3.0%) 169 (15.4%)
No surgery/no chemotherapy 9 (4.4%) 23 (2.1%) 124 (11.3%)
Table 2. Demographic and clinical characteristics of invasive epithelial ovarian cancer cases by subtype, New York and
Northern California. * Continuous variable presented as median (25th percentile, 75th percentile).
Figure 1. Adjusted relationship between age and risk of mucinous epithelial compared to serous epithelial ovarian
cancer. Solid line indicates log-odds ratio, dotted lines indicated confidence intervals.
Table 3, Figure 1 and Figure 2 show the demographic and clinical characteristics significant‐
ly associated with mEOCs compared to other epithelial ovarian cancers, after adjusting for
other factors. mEOCs were more often associated with Asian non-Hispanic race/ethnicity
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compared to serous tumors (odds ratio [OR] 1.94, 95% confidence interval [CI] 1.13-3.35).
The relationship between age and epithelial subtype was nonlinear; ages 55 years and
younger were more often associated with mEOC compared to both serous and other EOCs
(Figures 1 and 2). Less advanced stage was associated with mEOCs compared to serous
EOC (OR 0.29, 95% CI 0.18-0.47 for stage III and 0.39, 0.19-0.78 for stage IV). mEOCs were
less likely to be grade III/IV compared to serous (OR 0.11, 95% CI 0.07-0.20) and other EOC
(OR 0.10, 95% CI 0.06-0.16). Bilateral ovarian cancer at diagnosis was less often associated





Mucinous vs. Other Epithelial
Odds Ratio
95% CI
Age at diagnosis* 0.0008 Nonlinear Nonlinear
Nonlinear 0.0002
Race/Ethnicity 0.0723
White non-Hispanic 1.00 1.00
Black non-Hispanic 1.36 (0.73-2.54) 1.52 (0.82-2.80)
Asian non-Hispanic 1.94 (1.13-3.35) 1.17 (0.72-1.90)
Hispanic 0.77 (0.40-1.50) 0.76 (0.40-1.44)
FIGO Stage <.0001
I 1.00 1.00
II 0.89 (0.50-1.60) 0.96 (0.57-1.63)
III 0.29 (0.18-0.47) 1.10 (0.70-1.72)
IV 0.39 (0.19-0.78) 0.68 (0.35-1.32)
Unknown 0.41 (0.21-0.83) 0.80 (0.41-1.57)
Grade <.0001
I 1.00 1.00
II 0.62 (0.38-1.00) 0.49 (0.31-0.77)
III/IV 0.11 (0.07-0.20) 0.10 (0.06-0.16)
Unknown 0.92 (0.55-1.55) 0.31 (0.19-0.49)
Laterality <.0001
Unilateral 1.00 1.00
Bilateral 0.32 (0.22-0.49) 0.80 (0.53-1.21)
Table 3. Adjusted odds ratios and 95% confidence intervals for demographic and clinical characteristics of invasive
epithelial ovarian cases by subtype, New York and Northern California. *The relationship between age and histologic
subtype is shown in Figures 1 and 2.CI=confidence interval
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Figure 2. Adjusted relationship between age and risk of and mucinous epithelial ovarian cancer compared to other
epithelial ovarian cancer. Solid line indicates log-odds ratio, dotted lines indicated confidence intervals.
3.2. Survival following a mucinous ovarian cancer diagnosis
Unadjusted Kaplan-Meier estimates showed that survival following an epithelial ovarian
cancer diagnosis was initially worse for mEOC and other EOC compared to serous EOC
(Figure 3). At approximately 38-40 months post-diagnosis, mEOC and other EOC tumor sur‐
vival rates stabilized, whereas survival from serous EOC continually decreased. At the end
of the 6 year follow-up period, survival was significantly different among the epithelial sub‐
types (log rank p<0.001). Unadjusted survival was 49.8% among women with mEOC, 39.0%
among women with other EOC, and 30.8% among women serous EOC.
The results of the multivariable Cox model predicting 6-year survival are shown in Table 4
and Figure 4. After adjustment, black race, advanced stage, higher grade, and the presence
of comorbidities were all associated with increased mortality from EOC (Table 4), as was in‐
creasing age (especially age > 60, Figure 4). By epithelial subtype, mEOC conferred a worse
prognosis and was associated with increased mortality compared to both serous EOC (Haz‐
ard ratio [HR] 0.51, 95% CI 0.40-0.65), and other EOC (HR 0.56, 95% CI 0.44-0.72). Significant
interactions were found between epithelial subtype and both surgery (p=0.0064) and chemo‐
therapy (p=0.0340). In all cases, mEOC was associated with increased mortality. Significant
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associations occurred among those who received both surgery and chemotherapy; women
with serous EOC and other EOC had better survival than those with mEOC in this group
(serous HR 0.45, 05% CI 0.33-0.62; other EOC HR 0.44, 95% CI 0.32-0.61). This was also the
case for women who were treated with chemotherapy alone (serous EOC HR 0.16, 95% CI
0.07-0.38; other EOC HR 0.40, 95% CI 0.20-0.81). In women who received only surgery or did
not receive treatment, those with serous EOC had better survival than those with mEOC
(HR 0.65, 95% CI 0.42-1.00, HR 0.23, 95% CI 0.10-0.53, respectively).
Figure 3. Six-year survival following an invasive epithelial ovarian cancer diagnosis by subtype, New York and North‐
ern California
Characteristic Wald χ2 DF* P-value Hazard Ratio(95% CI)
Age at diagnosis* 99.68 2 <0.0001
Nonlinear 10.75 1 0.0010
Race/Ethnicity 26.63 3 <0.0001
White non-Hispanic 1.00
Black non-Hispanic 1.47 (1.17-1.86)
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Characteristic Wald χ2 DF* P-value Hazard Ratio(95% CI)
Asian non-Hispanic 0.62 (0.45-0.84)
Hispanic 0.76 (0.59-0.98)
FIGO Stage 239.24 4 <0.0001
I 1.00
II 1.40 (0.96- 2.04)
III 4.96 (3.77- 6.51)
IV 8.02 (5.93-10.84)
Unknown 5.36 (3.93- 7.31)





Laterality 38.41 2 <0.0001
0 – 2 years
Bilateral vs. Unilateral 1.04 (0.87-1.23)
"/>2 years – 6 years
Bilateral vs. Unilateral 1.86 (1.53-2.27)
Comorbidity 20.04 2 <0.0001
0 1.00
1 1.26 (1.08-1.48)
2 or more 1.59 (1.26-2.01)
Epithelial subtype** 48.68 6 <0.0001
Mucinous 1.0
Serous 0.51 (0.40-0.65)
Other Epithelial 0.56 (0.44-0.72)
Surgery+Chemotherapy
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Characteristic Wald χ2 DF* P-value Hazard Ratio(95% CI)
Mucinous 1.0
Serous 0.45 (0.33-0.62)








Other Epithelial 0.40 (0.20-0.81)
No Surgery/ No Chemotherapy
Mucinous 1.0
Serous 0.23 (0.10-0.53)
Other Epithelial 0.75 (0.38-1.49)
Surgery (Yes vs. No) 34.93 3 <0.0001
Mucinous 0.38 (0.20-0.75)
Serous 1.06 (0.63-1.79)
Other Epithelial 0.42 (0.31-0.58)
Chemotherapy (Yes vs. No) 11.05 3 0.0115
Mucinous 1.25 (0.79-1.97)
Serous 0.88 (0.68-1.14)
Other Epithelial 0.67 (0.51-0.87)
Table 4. Multivariate proportional hazards results of invasive epithelial ovarian cancer cases, New York and Northern
California. *The relationship between age and risk of death is shown in Figure 4. **The overall epithelial subtype
comparisons are from a model excluding the subtype and treatment interactions. These are presented to show the
“average” effect across treatments. All other hazard ratios in the model are calculated from the model including the
interactions.




This large, population-based study adds further, definitive evidence for demographic and
clinical characteristics previously associated with mEOC: Asian race, early stage, low grade,
and unilateral ovarian involvement at diagnosis [9,16,28]. Regardless of the large proportion
of stage I diagnoses (about 45%), mEOC appears to be a particularly deadly subtype of ovar‐
ian cancer. These patterns seen in mEOC are consistent with clear cell EOC, which also
tends to be diagnosed at early stages [29], and has poor overall survival compared to other
EOCs [29,30]. Patterns of other epithelial subtypes vary: endometrioid EOC is often diag‐
nosed at early stages, but generally has better overall survival compared to other EOCs [31];
serous EOC is most often diagnosed at late stages (stage III and IV), and survival from these
tumors appears to be significantly associated with grade [32]. These divergent patterns sug‐
gest that EOC is an extremely heterogeneous group, and histologic subtype should be con‐
sidered in addition to stage before and during treatment.
Figure 4. Adjusted relationship between age and risk of death within six years following an epithelial ovarian cancer
diagnosis. Solid line indicates log-hazard ratio, dotted lines indicate 95% confidence intervals.
The  poor  survival  from  mEOC  shown  here  is  consistent  with  other  studies  [14,16,33]
and may be due to a decreased response to chemotherapy. Our study results are consis‐
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tent with these findings, in that chemotherapy did not appear to have a beneficial effect
in women with mEOC. Evidence suggests  that  mEOC response rates  to platinum-based
chemotherapy are low overall (13-26%) [14,34]. This decreased response could be related
to  a  lack  of  sensitivity  of  mEOCs  to  standard  platinum-containing  chemotherapy  regi‐
mens [17].  It  is  well-established that  platinum sensitivity varies by pathologic and clini‐
cal  characteristics  including  tumor  type  [34,35].  Relatively  recently,  some groups  in  the
United States have suggested that different treatment strategies should be considered for
mEOC,  and  that  future  clinical  trials  should  be  redesigned  to  1)  exclude  women  with
mEOC  and  other  rare  EOC  types  [36],  and  2)  assist  with  the  development  of  novel
agents more targeted to mEOC that can be used in the front-line and recurrent settings
[17,  37].  Several  barriers  exist  to  such  clinical  trials,  including  decreased  availability  of
funding [38],  as  well  as  potential  lack of  enrollment  and participation due to  the rarity
and deadly nature of mEOC. Despite these limitations however,  a phase III  clinical trial
comparing standard carboplatin and paclitaxel regimen (with and without bevacizumab)
to oxalitlatin and capecitabine (with and without bevacizumab) in women with stages II-
IV or recurrent untreated stage I primary mEOC was recently announced [39].
Some groups have suggested additional chemotherapeutic agents that may be more effec‐
tive in the treatment of mEOC. Based on studies with mEOC cell lines, combination chemo‐
therapy consisting of oxaliplatin and 5-fluorouracil may be beneficial for mEOCs [40]. The
suggested use of fluorouracil, a chemotherapy agent used in the treatment of colon cancer
[41], has gained additional support because of the similarities between mEOC and mucinous
tumors of the colon [16,42]. A recent review comparing characteristics of these two tumor
types concluded that there are multiple similarities with respect to mutational patterns, clin‐
ical presentation, therapy response, and outcomes [43]. The review further proposes that the
search for new and more effective chemotherapeutic agents for mucinous tumors might be
more successful if comparisons are made across organs [43]. However, there are clear differ‐
ences in the cellular localization of mucin in these two types, and further research is needed
to substantiate the usefulness of this approach.
Regardless of the availability of and evidence for alternative treatment regimens, the results
presented here underscore the need for precise pathologic assessment of all EOCs with re‐
spect to site of tumor origin, histologic type and subtype, behavior and grade. The vast ma‐
jority of histologic-specific analyses using medical record data (including this one) are
limited by the fact that there is no central pathology review of included cases. Because of
this, a few studies have retrospectively reviewed stored specimens and medical records to
examine concordance of pathologic characteristics of ovarian cancer. In a population-based
study using Surveillance Epidemiology and End Results (SEER) data, there was 98% con‐
cordance on site of origin, and 97% concordance on overall epithelial histologic type [44].
Concordance varied by histologic subtype; it was 100% for clear cell EOC, 87% for mEOC,
80% for serous EOC, and 73% for endometrioid EOC. For tumor behavior, there was 85%
concordance for invasive ovarian tumors. In most cases (90%), tumors originally diagnosed
as invasive were thought to be low malignant potential upon review. Another study exam‐
ining pathology in the Gilda Radner Familial Ovarian Cancer Tumor Registry reported
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95.3% concordance on primary site [45]. The agreement by histologic subtype was lower,
with disagreement on 38.3% of cases. The vast majority of differences were related to differ‐
ences in classification of serous EOC, either by the initial or reviewing pathologist. Concord‐
ance by grade was slightly better than that by histologic subtype, with disagreement on
31.2% of cases. The majority of differences centered on the differential assignment of grade
II versus grade III. Few cases (a total of 7.6%) were upgraded or downgraded in a way that
would have potential implications for treatment. While these pathologic review findings are
encouraging overall and provide support for analyses of mEOC such as this one, they may
not be exact enough to support the prescription of alternative treatment regimens based
solely on histologic subtype.
5. Conclusions
The results presented here provide definitive evidence that mEOC is associated with differ‐
ent demographic and clinical characteristics than other EOC subtypes, and women diag‐
nosed with mEOC have worse adjusted survival compared to those with other EOC
subtypes. A particular strength of this study is the population-based approach, which re‐
flects the experience of two U.S. populations of women with ovarian cancer, as opposed to
that of a single institution or those participating in clinical research. This study yields sever‐
al implications for future research. First and foremost, the continued characterization of the
heterogeneity of ovarian cancer through basic, clinical, and population research is necessary.
Second, the need for precision in pathologic assessments is paramount, and pathologists, on‐
cologists and scientists all have a role in assisting with this through research and education.
Finally, assessment of provider knowledge and awareness regarding treatment recommen‐
dations, and proposed or enacted changes to these recommendations, would be beneficial
for ensuring appropriate use of evidence-based practices in the treatment of ovarian cancer.
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